

Supplemental Data for

Humoral immune responses to COVID-19 vaccination in people living with HIV on suppressive antiretroviral therapy

Zabrina L. Brumme^{1,2*}, Francis Mwimanzi¹, Hope R. Lapointe², Peter Cheung^{1,2}, Yuroou Sang¹, Maggie C. Duncan^{1,2}, Fatima Yaseen³, Olga Agafitei¹, Siobhan Ennis¹, Kurtis Ng¹, Simran Basra^{1,3,4}, Li Yi Lim^{1,3}, Rebecca Kalikawe¹, Sarah Speckmaier², Nadia Moran-Garcia², Landon Young⁵, Hesham Ali⁶, Bruce Ganase⁷, Gisele Umvilighozo¹, F. Harrison Omondi^{1,2}, Kieran Atkinson², Hanwei Sudderuddin^{2,8}, Junine Toy², Paul Sereda², Laura Burns⁹, Cecilia T. Costiniuk¹⁰, Curtis Cooper^{11,12}, Aslam H. Anis^{13,14,15}, Victor Leung^{5,16}, Daniel Holmes^{9,16}, Mari L. DeMarco^{9,16}, Janet Simons^{9,16}, Malcolm Hedgcock¹⁷, Marc G. Romney^{5,16}, Rolando Barrios^{2,13}, Silvia Guillemi^{2,18}, Chanson J. Brumme^{2,8}, Ralph Pantophlet^{1,3}, Julio S.G. Montaner^{2,8}, Masahiro Niikura¹, Marianne Harris^{2,18}, Mark Hull^{2,8}, Mark A. Brockman^{1,2,3*}

¹ Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;

² British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada;

³ Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada;

⁴ Department of Chemistry, Simon Fraser University, Burnaby, Canada;

⁵ Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada;

⁶ John Ruedy Clinic, St. Paul's Hospital, Vancouver, Canada

⁷ AIDS Research Program, St. Paul's Hospital, Vancouver, Canada

⁸ Department of Medicine, University of British Columbia, Vancouver, Canada;

⁹ Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada;

¹⁰ Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre and Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

¹¹ Department of Medicine, University of Ottawa, Ottawa, Canada

¹² Ottawa Hospital Research Institute, Ottawa, Canada

¹³ School of Population and Public Health, University of British Columbia, Vancouver, Canada

¹⁴ CIHR Canadian HIV Trials Network, University of British Columbia, Vancouver, Canada

¹⁵ Centre for Health Evaluation and Outcome Sciences, Vancouver, Canada

¹⁶ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada

¹⁷ Spectrum Health, Vancouver, Canada

¹⁸ Department of Family Practice, Faculty of Medicine, University of British Columbia, Canada

Corresponding Author Contact Information:

Zabrina L. Brumme, Ph.D.

Professor, Faculty of Health Sciences

Simon Fraser University

8888 University Drive


Burnaby, BC, Canada, V5A 1S6

Tel: 778 782-8872

Fax: 778-782-5927


email: zbrumme@sfu.ca; zbrumme@bccfe.ca

Supplemental Figure 1



Supplemental Figure 1: Humoral immune response measurements pre- and post-vaccination *Panel A:* Binding antibody responses in COVID-19 naive PLWH (black circles), COVID-19 naive controls (grey circles) and COVID-19 convalescent individuals (colored as above) pre- and post-vaccination. Red dotted lines connect longitudinal measurements per participant. LLOD: assay lower limit of detection. ULOQ: assay upper limit of quantification. *Panel B:* Difference in \log_{10} binding antibody concentration between the first and second vaccine doses, with groups colored as above. P-values computed using the Mann-Whitney U test, and are uncorrected for multiple comparisons. *Panel C:* Same as A, except showing ACE2 displacement activity. Here, pre-vaccine measurements were only performed on a subset of 13 COVID-19 naive controls to estimate assay background, shown as grey shading. ND=not determined. *Panel D:* Same as B, except for ACE2 displacement activity.

Supplemental Figure 2



Supplemental Figure 2: Correlation between nadir CD4+ T-cell count and humoral vaccine responses. *Panel A:* Correlation between nadir CD4+ T-cell count and binding antibody responses after one dose (red circles) and two doses (blue circles). Dotted lines are to help visualize the trend. *Panel B:* same as A, but for ACE2 displacement activity.